Ambrilia Biopharma, Inc.
(AMB.TO) 0.02

1000 chemin du Golf, Verdun, Quebec, H3E 1H4 16 rue de la Banque, Paris, France 75002

Ambrilia Biopharma is developing small molecules and peptides to treat infectious diseases and cancer. Ambrilia’s product portfolio includes promising anti-HIV treatments, two new formulations of existing drugs developed with a patented technology, an anti-cancer therapeutic peptide, a tumor and tumor-vasculature targeting (TVT) technology platform, as well as other anti-virals and immunomodulators.

Angiotech Pharmaceuticals Inc
(ANPI) 0.45

6660 North West Marine Drive 6660, BRITISH COLUMBIA V6T 1Z4

Angiotech Pharmaceuticals Inc. The principal activities of the Company is to develop and commercialize the new treatment for chronic inflammatory and agiognesis dependent diseases based upon paclitaxel and realted compound formulations. The Company operated in two business segments: medical device coating/implants and therapeutics. The medcial device coating/implants segment comprise the research and development of drug loaded coatings for medical devices and drug loaded medical implants. The therapeutics provides the research and development of pharmaceuticals for the treatment of chronic inflammatory diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. Medical device coatings/Implants accounted for 99% of fiscal 2001 revenues and Therapeutics, nominal.

Aspreva Pharmaceuticals

#1203, 4464 Markham St, Victoria, BC V8Z 7X8 CANADA

Aspreva Pharmaceuticals is a pharmaceutical company which identifies, develops and commercializes new applications for existing medicines. The medicines we choose to develop are anticipated to have high therapeutic value for underserved diseases. We define 'underserved' as those populations for which there is currently a lack of adequate treatment options and few if any treatments in development. This encompasses rare diseases, less common diseases and neglected diseases. Our mission is to increase the pool of evidence-based medicines for these underserved patient populations.

Axcan Pharma Inc

597 Laurier Blvd, Mont Saint-Hilaire, Quebec CANADA J3H 6C4 La Prévôté - Route du Bû 78550 Houdan, FRANCE 22 Inverness Center Parkway Birmingham, AL 35242

By combining the successes of our internal research and development efforts with our product-licensing strategy, we have built a strong research and development pipeline filled with promising products. Our diverse pipeline mitigates the risks of drug development because we have a balanced mix of both short-and long-term opportunities in the development of products for various functions of the gastrointestinal system.

Biomatik
*VENDOR/SERVICE*

25 Harris St., Unit 101 Cambrige, Ontario N1R 7B6 CANADA

Privately owned, based in Ontario Canada, Biomatik specializes in custom gene and peptide synthesis, siRNA construction, and polyclonal as well as monoclonal antibody production. Biomatik also offers wide ranges of products including biochemicals & enzymes; molecular biology kits; RNA, DNA modifying enzymes; PCR related products; markers and vectors; culture mediums and labwares.

Biomira Inc
(BIOM) 0.54

2011 - 94 STREET,EDMONTON ALBERTA T6N 1H1 CANADA 221 East 6th Street Tucson, AZ 85705

Biomira is a biotechnology, healthcare company dedicated to the research, development and commercialization of products for the diagnosis and treatment of cancer. The company utilizes proprietary and patentable methods in the development, manufacture and marketing of products for the diagnosis and therapy of cancer. Biomira is also concerned with the manufacture and marketing of diagnostic test kits for sexually transmitted and infectious diseases including hepatitis. Biomira's subsidiaries include Biomira USA Inc. (BioUSA) and Biomira (Barbados) Inc. (BBI). During 1999 Biomira took enormous strides advancing its diverse product pipeline and continuing clinical development of three cancer vaccine candidates-targeting the most significant cancer markets in the world.

Biovail
(BVF) 26.51

2488 Dunwin Dr, Mississauga ONTARIO L5L 1J9 CANADA

Biovail Corporation is a full-service pharmaceutical company that applies its proprietary drug delivery technologies in developing "oral controlled-release" products throughout North America. Biovail applies its proprietary drug delivery technologies to successful drug compounds that are free of patent protection to develop both branded and generic oral controlled-release products. The branded oral controlled-release products improve on existing formulations, providing better therapeutic and economic benefits.

Chromos Molecular Systems

8081 Lougheed Highway, Burnaby, British Columbia CANADA V5A 1W9

Chromos is a biopharmaceutical company with two drug development programs focused on inflammatory diseases and thrombotic disorders.

Coley Pharmaceutical Group
(COLY) 0.00

93 Worcester Street, Suite 101, Wellesley, MA 02481 340 Terry Fox Drive, Suite 200 Ottawa, Ontario, K2K 3A2 CANADA Elisabeth-Selbert-Strasse 9 D40764 Langenfeld, GERMANY

Coley is focused on the discovery, development and commercialization of TLR Therapeutics that direct the immune system to fight disease. TLR Therapeutics™ act by stimulating a specific class of targets, called Toll-like receptors, or TLRs, found in and on immune system cells which, in turn, direct the immune system to fight disease. TLRs detect molecules that are unique to foreign invaders, or pathogens, and which distinguish intracellular pathogens, such as viruses and retroviruses, from extracellular pathogens, such as most bacteria and fungi. Our TLR Therapeutics are synthetic nucleic acids that function as stimulators, or as blockers, of one or more TLRs that are found in immune cells. Each of our product candidates are all short DNA-like molecules, with distinct motifs, or nucleotide sequences, that possess potent immunomodulatory properties which direct different immune system functions.

ConjuChem
(CJB.TO) 0.00

225, President-Kennedy Ave., 3rd Floor, Suite 3950, Montreal, Quebec CANADA H2X 3Y8

ConjuChem is currently managing several research programs in-house and has one product in clinical development. We are focused on discovering and developing new drugs based on our novel technology platforms called Drug Affinity Complex (DACTM) and Preformed Conjugate-Drug Affinity Complex (PC-DACTM). When applied to a compound, DACTM or PC-DACTM can create a new drug with similar therapeutic activity but a significantly longer duration of activity in the body. One of the greatest opportunities for the DACTM and PC-DACTM technology from ConjuChem is its ability to harness the therapeutic potential of peptides, which are hindered by a variety of limitations.

Forbes Medi-Tech Inc.
(FMTI) 0.00

Suite 200 - 750 West Pender Street, Vancouver, BC V6C 2T8 CANADA

Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment primarily of cardiovascular disease (CVD).

Gemin X Pharmaceuticals, Inc.

3576 Avenue du Parc, Suite 4310 Montreal, QC, H2X 2H7 Canada 400 Chesterfield Parkway, Suite 100, Malvern, PA 19355

Gemin X Pharmaceuticals, Inc., specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X's second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT), resulting in cancer cell death independently of the tumor suppressor p53. It is currently in Phase 1 clinical trials in patients with refractory solid tumors and lymphomas. Gemin X is privately held and is located in Malvern, Pennsylvania and Montréal, Québec.

GeneMax Pharmaceuticals

1681 Chestnut Street, Suite 400 Vancouver, BC, Canada, V6J 4M6

GeneMax develops innovative immunotherapies in the fields of oncology and infectious disease. Our patented technology restores or increases antigen processing and antigen specific immune responses. GeneMax has demonstrated preclinical efficacy in animal models of lung cancer and melanoma as well as proof of principle for infectious disease pathogens. GeneMax’s program also includes developing a therapeutic vaccine for diseases caused by the Human Papilloma Virus. This virus is known to cause cervical cancer, head and neck cancer, and respiratory papillomatosis. A second program is advancing to leverage GeneMax’s enabling technology for partnering with companies developing prophylactic vaccine products for infectious disease.

GeneNews

800 Petrolia Road, Unit 15, Toronto, Ontario, Canada M3J 3K4

GeneNews Limited (formerly ChondroGene Limited) was formed in 1998 by its two founders; Dr. K. Wayne Marshall, a noted orthopaedic surgeon and knee specialist and Dr. C.C. Liew, an internationally recognized leader in the area of tissue-specific functional genomics. GeneNews was founded to focus on the identification of novel therapeutic targets for a single disease, osteoarthritis. At that time, the company was interested in the gene expression of cartilage cells called chondrocytes, hence the name ChondroGene. The goal was to examine how the tissues of the joint function in different stages of osteoarthritis; from normal joints, to moderately diseased joints, all the way to severe osteoarthritis which can be treated only by total joint replacement. Genenews’ work on Osteroarthritis led to two collaborations with Pfizer Inc.

Generex Biotechnology
(GNBT) 0.41

33 Harbour Square, Suite 202, Toronto, Ontario, Canada M5J 2G2

Generex Biotechnology Corporation has developed a proprietary platform drug delivery technology, RapidMist™, that administers medications directly into the mouth as a metered-dose spray, for rapid absorption by the buccal mucosa. This technology has been specially designed for the pain-free, accurate, and safe delivery of drugs. The Company's flagship product, Generex Oral-lyn™, is the first application for RapidMist and is currently in late stage clinical trials around the world.

Inex Pharmaceuticals
(TKM.TO) 1.68

200 - 8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8

*Changed name from Inex Pharmaceuticals in early 2007*
Tekmira Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer.

Inflazyme Pharmaceuticals
(IZP.TO) 0.00

425 - 5600 Parkwood Way, Richmond, British Columbia, Canada V6V 2M2

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies to improve the lives of people with respiratory and inflammatory diseases. Our lead program, the LSAIDs™, are small molecules that have unique anti-inflammatory properties together with certain physical, chemical and biological features that make them suitable as potential once, or twice a day, oral medicines. Since our LSAIDs™ have demonstrated clear efficacy in several models of lung inflammation, our target diseases are asthma, allergic rhinitis and COPD. The basis of our second program are inhibitors of an enzyme called phosphodiesterase 4 (PDE4). The PDE4 program is also based on a natural product, on this occasion a chemical isolated from a medicinal plant, discovered by Inflazyme's scientists. Inhibition of the PDE4 enzyme is important in controlling the activities of leukocytes by preventing the release of chemicals that can harm the body.

Isotechnika
(ISA.TO) 0.33

5120 - 75th Street, Edmonton, Alberta T6E 6W2 Canada

Isotechnika Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of novel immunosuppressive therapeutics for the treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. In addition to the Company’s drug pipeline, Isotechnika also has diagnostic products.

Kiadis Pharma

Zernikepark 6-8, 9747 AN Groningen, The Netherlands 2525 ave. Marie-Curie Saint-Laurent (Quebec) CANDA H4S 2E1

*Kiadis merged with Celmed in Dec 2007*
Kiadis Pharma dedicates its resources to the development of groundbreaking, novel treatments for end-stage cancer patients.

Lorus Therapeutics, Inc.
(LRP) 0.00

2 Meridian Rd, Toronto, Ontario CANADA M9W 4Z7

Lorus is a biopharmaceutical company focused on the discovery, research and development of innovative and effective anticancer therapies with a high safety profile. Through its own discovery and R&D efforts as well as partnership, in-licensing and acquisition programs, the Company is building a portfolio of promising anti-cancer drugs with low toxicities.

Methylgene, Inc.
(MYG.TO) 0.17

7220 Frederick-Banting, Montreal, Quebec H4S 2A1 Canada

MethylGene is focused on the discovery, development and commercialization of novel therapeutics for cancer. The company focuses on some of the most promising areas of oncology such as histone deacetylase (HDAC) and kinase inhibitors. The Company's lead product is MGCD0103, an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematalogical malignancies including Phase II monotherapy trials and Phase I/II combination trials with Vidaza® and Gemzar®. MGCD265 is an oral multi-targeted kinase inhibitor targeting the c-MET and VEGF receptor tyrosine kinases.

Migenix

BC Research Building, 3650 Wesbrook Mall, Vancouver, B.C. V6S 2L2 Canada 12780 High Bluff Drive, Suite 210, San Diego, CA 92130

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the prevention and treatment of major medical diseases and certain conditions with unmet medical need. With its expertise and experience in product development, the Company is focused on advancing its pipeline of product candidates in the areas of infectious and degenerative diseases.

Nanogen, Inc
(NGEN.PK) 0.01

10398 Pacific Center Court, San Diego, CA 92121 21720 23rd Drive SE, #150, Bothell, WA 98021 1 Marmac Drive, Toronto, Ontario, Canada M9W 1E7 Corso Torino 89/d, 10090 Buttigliera Alta (TO), Italy

Nanogen’s technologies are uniquely bridging the gap between early-stage scientific research and actual clinical practice. We are committed to helping the healthcare community realize the benefit of molecular diagnostics and to improving patient care through advances in the diagnosis of disease and the evaluation of particular therapies for individual patients.

Neurochem

275 Armand-Frappier Blvd., Laval, Québec, Canada H7V 4A7

Neurochem is focusing on the further development of promising drug candidates currently in clinical trials for AA amyloidosis, Alzheimer's disease, and hemorrhagic stroke due to cerebral amyloid angiopathy.

NPS Pharmaceuticals
(NPSP) 6.40

Morris Corporate Center 1, 4th Floor, Building B, 300 Interpace Parkway, Parsippany, NJ 07054 383 Colorow Drive, Salt Lake City, UT 84108 30 College Street, Suite 301, Toronto, Ontario M5G 1K2 CANADA

NPS Pharmaceuticals is engaged in the discovery, development and commercialization of therapeutic small molecules and recombinant proteins to treat bone and mineral, gastrointestinal and central nervous system disorders.

Nventa Biopharmaceuticals
(NVN.TO) 0.00

9381 Judicial Drive, Suite 180, San Diego, CA 92121 #120 - 4243 Glanford Avenue, Victoria, BC Canada V8Z 4B9

Nventa Biopharmaceuticals Corporation is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company’s lead initiative is the development of HspE7, a therapeutic vaccine for the possible treatment of patients with cervical dysplasia, recurrent respiratory papillomatosis and genital warts.

Nymox Pharmaceutical Corp
(NYMX) 3.65

Heights Plaza, 777 Terrace Avenue 3rd Floor, Hasbrouck Heights, NJ 07604 9900 Cavendish Boulevard, Suite 306, St.-Laurent, Quebec, Canada H4M 2V2

Nymox Pharmaceutical is specializing in the research and development of therapeutics and diagnostics for the aging population. Nymox has an extensive pipeline of products under development, including therapeutics for enlarged prostate (BPH), a common affliction of males over the age of 50, and for Alzheimer's disease, the most common cause of dementia in the elderly. The company has global patent rights for the use of statins to treat or prevent Alzheimer’s disease. Nymox also has therapeutics in development for other indications, including deadly E. coli O157 food contamination, a major public health concern.

Oncolytics Biotech, Inc.

210, 1167 Kensington Crescent NW, Calgary, AB CANADA T2N 1X7

Oncolytics Biotech focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers. The Company was formed in 1998 to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.

Prometic Life Sciences, Inc.

8168 Montview Road, Mount-Royal, Québec Canada H4P 2L7

Our therapeutic business model is to bring to market effective innovative, safer, lower cost therapeutic products for the treatment of cancer and autoimmune diseases / inflammation.

Qlt Inc.
(QLTI) 6.11

887 Great Northern Way, Vancouver, BC, Canada V5T 4T5 2579 Midpoint Drive, Fort Collins, CO 80525

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®.

Theratechnologies, Inc.
(TH.TO) 4.95

2310 Alfred-Nobel Blvd., Montréal, Québec CANADA H4S 2A4

The Company has a portfolio of products at various stages of development. The clinical development program for our lead product, TH9507, a growth hormone-releasing factor analogue, in HIV-associated lipodystrophy is currently in Phase 3 and includes two clinical trials (the second of which is intended to confirm the first). In addition, we are exploring further development of TH9507 for applications in other indications. Growth hormone deficiency in adults and management of cystic fibrosis are among the indications currently being considered by the Company.

Tranzyme Pharma

4819 Emperor Blvd, Suite 400, Durham, NC 27703 001 12e Avenue Nord, Sherbrooke, QC, J1H 5N4, CANADA

Tranzyme Pharma is developing novel small molecules targeting key validated G protein-coupled receptors (GPCRs) that regulate gastrointestinal motility, appetite and metabolism. These GPCRs include ghrelin (responsible for upper gut motility, appetite stimulation, and energy balance) and motilin (responsible for regulation of gastrointestinal transit).

Trillium Therapeutics

96 Skyway Ave., Toronto, Ontario Canada M9W 4Y9

Trillium Therapeutics specializes in the discovery and development of innovative therapies for the treatment of immune-mediated disorders. The company’s therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, graft rejection, cancer and chronic viral diseases. TTI is primarily involved in the development of protein therapeutics, such as monoclonal antibodies, secreted proteins and peptides.

Vasogen, Inc.
(VSGN) 0.26

2505 Meadowvale Blvd., Mississauga, Ontario, L5N 5S2, Canada

We are a biotechnology company engaged in the research and development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. Our lead product, the Celacade™ technology, is designed to trigger the immune response to apoptosis — an important physiological process that regulates inflammation. Celacade is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. We are also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders and are preparing to advance VP025, the lead drug candidate from this new class, into phase II development.

ViRexx Medical Corp
(REX) 13.47

8223 Roper Road NW, Edmonton, Alberta, CANADA T6E 6S4

ViRexx is focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections. ViRexx's most advanced clinical programs include drug candidates for the treatment of ovarian cancer, chronic Hepatitis B & C and solid tumors.

Viventia Biotech Inc.

10 Four Seasons Pl, Suite 501, Toronto, ONTARTIO CANADA, M9B 6H7

Viventia Biotech is advancing a portfolio of novel antibody products focused on cancer. Proxinium™, our lead product, is undergoing a multinational pivotal Phase II/III clinical trial for the treatment of head and neck cancer. We are also developing Vicinium™, which is entering a Phase II clinical study for the treatment of bladder cancer, along with a portfolio of earlier-stage drugs.

Xenon Pharmaceuticals, Inc.

3650 Gilmore Way Burnaby, BC V5G 4W8 CANADA

Xenon is a clinical genetics-based drug development company. Our products XEN401, XEN501, and inhibitors of DMT1 are innovative drugs with the potential to transform patient care in pain, arrhythmia, and iron overload. The drug targets for these products are known to exert a major effect on the disease of interest as they were identified using both human and mouse genetic studies. We also have partnered programs including SCD1 inhibitors for metabolic diseases with Novartis, atherosclerosis discovery with Takeda, and anemia of inflammation with Roche.

YM Biosciences, Inc.

5045 Orbitor Drive, Building 11, Suite 400, Mississauga, Ontario CANADA L4W 4Y4

YM BioSciences Inc., is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF™, a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.